Table 3.
Significant prognostic factors for 5-year LRR by multivariate regression analyses
| Variables | Multivariate analyses | ||
|---|---|---|---|
| LRR | |||
| HR | 95%CI | p | |
|
1999–2007 vs. 2008–2014 |
1.923 | 1.380–2.688 | < 0.001 |
|
Age ≤ 40 years old vs. > 40 years old |
2.262 | 1.646–3.107 | < 0.001 |
|
Inner location vs. Non-inner location |
2.236 | 1.787–2.798 | < 0.001 |
|
T2 stage vs. T1 stage |
1.419 | 1.061–1.898 | 0.018 |
|
ER/PR (−) vs. ER and PR(+) |
1.485 | 1.042–2.117 | 0.029 |
|
LVI vs. without LVI |
1.053 | 0.879–1.262 | 0. 575 |
|
Grade III vs. Grade I and II |
1.237 | 0.8861.726 | 0. 212 |
|
IDC vs. other pathology type |
0.848 | 0.715–1.006 | 0.059 |
|
Adjuvant chemotherapy vs. non-adjuvant chemotherapy |
1.429 | 0.951–2.147 | 0.086 |
|
Endocrine therapy vs. non- Endocrine therapy |
0.728 | 0.524–1.012 | 0.059 |
|
Anti-Her2 target therapy vs. non- Anti-Her2 target therapy |
0.606 | 0.246–1.492 | 0.276 |
ER Estrogen receptor, Her2 Human epidermal growth factor receptor 2, HR Hazard ratio, IDC Invasive ductal carcinoma, LRR Locoregional recurrence, LVI Lymphovascular invasion, PR Progesterone receptor